Kendle Names Louis A. Angelucci III Vice President, Validation

Article

Applied Clinical Trials

Angelucci Brings Global Experience in Validation, cGMP to Leadership Role in Regulatory Affairs Division

CINCINNATI, April 12, 2005 -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Louis A. Angelucci III as Vice President, Validation, for its AAC Consulting Group, Inc., subsidiary based in Rockville, Md. Angelucci will oversee the day-to-day operations of the validation unit and maintain the quality and consistency of its service to clients.

Angelucci most recently served as Senior Director of Validation and Compliance in the life sciences division of global engineering and construction firm Technip. His prior experience includes serving as Vice President of Validation Operations for a major pharmaceutical firm, and responsibility for the global validation activities for two international companies.

"Lou brings more than 20 years experience in all aspects of cGMP, validation and validation project management to Kendle," says Edward A. Steele, Vice President of U.S. Regulatory Consulting and Submissions. "He also has experience working on commissioning, validation and cGMP issues with clients around the globe, and is familiar with U.S. and European regulations."

Angelucci earned Master of Science degrees in Engineering Management from Drexel University in 1990, and in Biomedical Engineering from the University of Pennsylvania in 1980. He earned a Bachelor of Science in biology from Ursinus College in 1977.

Angelucci is a member of the International Society of Professional Engineers (IPSE) and the board of directors of the Institute of Validation Technology (IVT). He serves as adjunct professor at both Temple University and the Stevens Institute of Technology. He also is a member of the industry advisory board for the Stevens Institute.

About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions--from first-in-human studies through market launch and surveillance--to help the world's biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our more than 1,700 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street,Cincinnati, OH 45202, or from the company's Web site at www.kendle.com.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.